BANGKOK, March 03, 2025 — NewGenIvf Group Limited (NASDAQ: NIVF) (“NewGen”), an Asian fertility services provider, has announced a strategic collaboration with BOBCARE FERTILITY GROUP LLC (“BOBCARE”) to jointly develop fertility services in Kyrgyzstan.

The collaboration seeks to leverage NewGen’s fertility treatment expertise and BOBCARE’s regional market resources. This partnership is expected to enhance NewGen’s market presence over the next three years and improve both companies’ competitive standing in Kyrgyzstan. The companies will collaborate on initiatives such as improving clinical protocols and patient management, facilitating knowledge exchange between specialists, coordinating marketing and branding in Kyrgyzstan, and developing specialized fertility treatment options for the region.

Kyrgyzstan is an emerging market for fertility services in Central Asia, demonstrating interest in healthcare investments and a growing demand for advanced reproductive technologies. The country has a young population with evolving attitudes towards fertility treatments. The collaboration aligns with strengthened economic cooperation between China and Kyrgyzstan as trade and investment partners under the “One-Belt-One-Road” initiative. BOBCARE, recently expanding its operations in Kyrgyzstan, provides valuable local market insights and established networks. NewGen brings its international experience and technical capabilities from its Asian operations.

“This collaboration with BOBCARE is a strategic opportunity to expand our services into an emerging market with significant growth potential,” said Mr. Siu Wing Fung Alfred, Founder, Chairman, and CEO of NewGen. “By combining our expertise with BOBCARE’s regional presence, we believe we can meet the increasing demand for quality fertility treatments in Kyrgyzstan and create value for our shareholders.”

Mr. Shi Lei, CEO of BOBCARE, stated, “Our partnership with NewGen is a significant step in BOBCARE’s globalization efforts. Through this collaboration, we aim to introduce leading Chinese reproductive healthcare professionals and technologies to Central Asia, enhancing our ability to offer patients a wide range of high-quality fertility treatment options.”

About NewGen

NewGen is a comprehensive fertility services provider in Asia, dedicated to helping couples and individuals access fertility treatments. Committed to assisting individuals and couples in building families, NewGen focuses on expanding access to infertility treatment and providing comprehensive services. The management team has over a decade of experience in the fertility industry. NewGen’s clinics, located in Thailand, Cambodia, and Kyrgyzstan, offer a full suite of services, including infertility and assisted reproductive technology treatments, egg and sperm donation, and surrogacy, where appropriate. For more information, visit . The information on NewGen’s website is not incorporated into this press release and should not be considered part of it.

About BOBCARE

BOBCARE is a leading Chinese platform for reproductive health and assisted reproduction services. With a high-standard service system, extensive market experience, and a broad user base, BOBCARE provides high-quality assisted reproduction services in China and globally, while promoting industry innovation and development. Initially funded by Matrix Partners, BOBCARE received strategic investment from WeDoctor Group, valued at $6.7 billion. Following restructuring within WeDoctor Group, BOBCARE became a key player in maternal and infant health. Since 2024, BOBCARE has focused on expanding operations and investments in Kyrgyzstan.

Forward-Looking Statements

This press release contains forward-looking statements made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are generally identified by terms like “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” and similar expressions. These statements include descriptions of the Company’s future operations, strategy, and financial condition. Forward-looking statements are predictions based on current expectations and assumptions, and are subject to risks and uncertainties. Many factors could cause actual events to differ materially from these statements, including the ability of NewGen and BOBCARE to successfully implement initiatives in Kyrgyzstan, the effectiveness of marketing efforts, cultural attitudes toward fertility treatments, and the reliance on the strategic partner’s expertise. You should carefully consider these factors and the risks described in the Company’s reports filed with the SEC, which could cause actual results to differ materially. Copies of these documents are available on the SEC’s website, www.sec.gov. The information in this release is current as of its date, and the Company undertakes no obligation to update any forward-looking statement, except as required by law.

Investor Relations Contact

ICR, LLC
Robin Yang
Phone: +1 (212) 537-4406
Email: 

“`